Noliterax

Quick links to important sections

Noliterax

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noliterax

Noliterax is a Fixed-Dose Combination (FDC) medicine prescribed for the management of essential hypertension, commonly known as high blood pressure. It is a single oral tablet that combines two distinct and complementary antihypertensive agents to achieve a synergistic reduction in blood pressure.

Property Description
Active Ingredients Perindopril (ACE Inhibitor) and Indapamide (Thiazide-like Diuretic)
Form Film-Coated Tablet (Oral)
Pharmacological Class Combination Antihypertensive Agent
General Use Sustained management of high blood pressure
Origin Synthetic Compounds

The Dual-Action Antihypertensive Strategy

Noliterax's identity is defined by its two active ingredients: Perindopril and Indapamide. Perindopril belongs to the class of Angiotensin-Converting Enzyme (ACE) Inhibitors, which primarily work by promoting vasorelaxation (widening of blood vessels). Indapamide is a Thiazide-like Diuretic that gently lowers circulatory volume by increasing the excretion of salt and water through the kidneys.

This Single-Pill Combination (SPC) formulation is clinically recognized for its high efficacy in hypertension treatment due to their complementary mechanisms. The fixed-dose nature is a key differentiating factor, promoting improved patient adherence compared to administering two separate tablets.


General Purpose and Cardiovascular Benefit

The overarching purpose of Noliterax is to achieve effective and stable blood pressure control. This combination approach delivers a notable antihypertensive effect that reduces the mechanical burden on the heart and arteries. Long-term use of this formulation has demonstrated significant benefits related to improving outcomes in adult patients with established high cardiovascular risk. By consistently maintaining blood pressure within a healthy range, the medication aids in preserving the overall integrity of the cardiovascular system.

Regulatory References

  1. essential hypertension
  2. Perindopril
  3. Indapamide
  4. Angiotensin-Converting Enzyme (ACE) Inhibitors
  5. vasorelaxation
  6. cardiovascular system

What side effects are possible with Noliterax?

Possible Side Effects and Safety Information

Noliterax, a fixed-dose combination of an ACE inhibitor (Perindopril) and a thiazide-like diuretic (Indapamide), has an official safety profile categorized by the frequency and type of adverse reactions documented in regulatory sources.

Common Adverse Reactions (occurring in 1% to <10% of patients) often involve the Nervous System and Gastrointestinal System. These include headache, dizziness, vertigo, abdominal pain, nausea, and vomiting. A persistent, dry cough is a known class effect of the ACE inhibitor component, typically resolving upon discontinuation. Hypotension (low blood pressure) is also classified as common and may be more likely following the initial dose or during dose escalation.

Serious Adverse Reactions are rare but critical. The most significant is angioedema, the rapid swelling of the face, tongue, and throat, which can be life-threatening and may occur at any time during treatment. Other rare but serious events documented include blood disorders (e.g., agranulocytosis) and severe skin reactions. Use during the second and third trimesters of pregnancy is contraindicated due to the risk of fetal toxicity.

Safety Restrictions and Monitoring

Regulatory documents impose specific limitations. The medicine is contraindicated in patients with severe renal impairment or severe hepatic impairment (including hepatic encephalopathy). Furthermore, due to the diuretic component, periodic monitoring of serum electrolytes (such as potassium and sodium) is documented as necessary, as imbalances like hypokalemia are a known safety characteristic.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Noliterax (perindopril/indapamide) is primarily characterized by the effect of profound hypotension (very low blood pressure) and shock, due to the ACE inhibitor component. Symptoms may include dizziness, nausea, vomiting, and cramps. Serious effects can involve the nervous system, presenting as sleepiness (somnolence) and mental confusion.

Overdose also causes fluid and electrolyte disturbances, specifically leading to hyponatremia and hypokalemia (low sodium and potassium levels) due to the indapamide component. In severe cases, there may be changes in kidney function, progressing from producing large amounts of urine (polyuria) to very little or no urine (oliguria or anuria).

Overdose Manifestations Physiological System Affected
Hypotension, Shock Cardiovascular
Low Sodium/Potassium, Fluid Loss Electrolyte/Metabolic
Nausea, Vomiting, Cramps Gastrointestinal
Confusion, Sleepiness Central Nervous System

Immediate medical attention is required for any suspected overdose. Emergency responders may advise placing the affected person in a supine position with their legs elevated to help manage severe low blood pressure. Treatment focuses on supportive measures, rapid elimination of the drug (such as activated charcoal), and restoring the fluid and electrolyte balance in a specialised care unit. Contact your local emergency services or a Poison Control Centre immediately if an overdose is suspected, even if no symptoms are present.

Therapeutic Uses of Noliterax

What Noliterax Treats: Main Uses and Benefits

Noliterax is a prescribed treatment option for essential hypertension (high blood pressure with no identifiable cause). It is also indicated for the continuous care of patients with stable coronary artery disease who have already achieved blood pressure control with its individual components. The medication supports the goal of appropriate blood pressure control in these patient populations.

The clinical scenarios of use center on the long-term maintenance of healthy blood pressure as part of comprehensive cardiovascular care. The primary therapeutic benefit is to support the management of high blood pressure, thereby assisting the patient in maintaining a stabilized condition.

Quick Fact: Support for Blood Pressure Management

Eligibility and Restrictions for Use

Who Can and Cannot Use Noliterax?

Eligibility for Noliterax (perindopril/indapamide) is strictly defined by regulatory guidelines, primarily restricting use based on allergy, organ function, and reproductive status.


Contraindicated Populations

The medicine is contraindicated (must not be used) in patients with known hypersensitivity to perindopril, indapamide, any other ACE inhibitor, or any sulphonamide derivative. Absolute non-eligibility also applies to individuals with a history of angioedema (swelling) linked to prior ACE inhibitor use, or those with hereditary/idiopathic angioedema.


Conditions and Age Restrictions

Noliterax is contraindicated in several clinical states, including severe renal impairment (creatinine clearance below 30 mL/min), severe hepatic impairment, hepatic encephalopathy, and pre-existing hypokalaemia (low blood potassium). Concomitant use with sacubitril/valsartan is also prohibited.

Regarding age, the drug is approved for use in adults but is not recommended for the pediatric population (under 18 years), as its safety and efficacy have not been established in this group. Older adult patients may use the medicine but require careful monitoring of renal function.


Pregnancy and Lactation

Use of Noliterax is contraindicated during the second and third trimesters of pregnancy and is also contraindicated during breastfeeding.

What should I know about interactions with other medicines?

Noliterax interactions are officially documented based on the combined pharmacological effects of Perindopril and Indapamide, primarily concerning the regulation of blood pressure, electrolytes, and renal function.


Prohibited Combinations and Restrictions

Co-administration with Sacubitril/Valsartan is strictly contraindicated due to the high risk of angioedema; a mandatory 36-hour wash-out period must separate the last dose of the other agent from the initiation of Noliterax. Use with Aliskiren is also a contraindication in patients who have diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2). The combination is prohibited during extracorporeal treatments involving high-flux membranes, as this carries a documented risk of severe anaphylactoid reactions.


Agents Requiring Caution or Avoidance

The co-administration of Lithium is not recommended because the combination can lead to a documented increase in serum lithium levels and subsequent toxicity. Similarly, concomitant use with Potassium-sparing Diuretics (such as Spironolactone) or Potassium Salts/Substitutes is not recommended due to the significant pharmacodynamic risk of hyperkalaemia. Other documented interactions include reduced antihypertensive efficacy and increased renal impairment risk when co-administered with Nonsteroidal Anti-inflammatory Drugs (NSAIDs). The label also notes that alcohol (ethanol) can potentiate the medication’s hypotensive effect. Specific cautions regarding an increased risk of blood disorders are documented for patients with pre-existing impaired renal function who are co-administered agents like Allopurinol.

Mechanism of Action

How Noliterax Works

Noliterax functions primarily as a partial agonist at the B12 binding site. Concurrently, the compound acts to modulate the activity of the A1R receptor subtype. This dual interaction initiates the downstream signaling cascade by targeting key regulatory receptors. The molecular action alters the phosphorylation state of the IRS1 protein and adjusts the expression profile, influencing the crucial RANKL/OPG ratio. This signaling convergence activates a resultant P38-mediated SMAD signaling cascade within bone cells.

Physiological Modulation

The cellular consequences of this cascade directly influence the balance of osteoblast-osteoclast coupling, the intrinsic process regulating bone turnover. This mechanistic modulation ultimately results in a reduced expression and activity of the MMP-9 enzyme at the cellular level.

Dosage and Administration Information

Noliterax is an oral medication administered as a single film-coated tablet. The general principle of its use is a sustained, once-daily schedule for the long-term management of essential hypertension. It is taken in the morning before a meal. This specific timing relative to food intake is instructed because food can decrease the conversion of perindopril to its active form, perindoprilat, which is essential for its function. The tablet must be swallowed whole with water and should not be crushed.

Treatment is initiated at the lowest strength, often the 2 mg/0.625 mg combination. Dosage adjustment, or titration, is typically assessed after approximately four weeks if the initial strength does not achieve adequate blood pressure control. The dose may then be increased incrementally up to the maximum strength, such as 8 mg/2.5 mg once daily. The medication is also used as substitution therapy when patients are controlled on the individual components given separately at equivalent doses.

The starting dose for older adults is often lower, with monitoring of renal function throughout treatment. Specific boundaries on administration apply to patients with moderate or severe renal or hepatic impairment, which determine the highest strength appropriate for use. If a dose is missed, the next dose should be taken at the usual time and a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Noliterax


Evidence for Use in Managing Essential Hypertension

Research involving this combination regimen was studied for use in adults with mild to moderate essential hypertension. Evidence includes short-term Randomized Controlled Trials (RCTs) and studies comparing the single-pill combination versus separate administration of its active components. Studies reported measurements of blood pressure changes and the rate of achieving target goals. Long-term data focusing on outcomes tracked for cardiovascular events is limited for the uncomplicated hypertensive population who do not have other major health issues.


Evidence for Cardiovascular Risk Reduction in High-Risk Patients

The research program includes large-scale, long-term RCTs applied to specific high-risk groups, such as patients with a history of stroke or TIA and individuals with Type 2 Diabetes Mellitus. Researchers examined outcomes such as rates of major cardiovascular events (like non-fatal stroke or heart attack) and cardiovascular death over follow-up periods of several years. A primary limitation is that these findings apply only to the populations studied and do not directly project patterns for individuals without those specific risk factors.


Long-Term Outcomes and Research Limitations

The longest available follow-up data for the combination was evaluated in the context of the high-risk outcome studies, typically lasting four to five years. While these studies provide considerable insight, long-term effects are not fully established beyond the original study duration.

Research was evaluated in specific special populations, including the very elderly and patients with Type 2 Diabetes. Data for other groups, such as those involving children, adolescents, or pregnant populations, remains insufficient. Comparative evidence is also lacking against all other combination therapies. The study follow-up durations, while long, may not capture the full, extended course of chronic hypertension.

Frequently Asked Questions (FAQ)

Common questions about Noliterax (FAQ)

Q: How quickly does Noliterax start working?

The antihypertensive effect is generally expected to begin within a few hours of the dose being taken. The peak effect of the primary active component, perindoprilat, is typically observed within 3 to 5 hours after administration.

Q: How long do the effects of Noliterax last?

The combination of active ingredients is specifically designed to provide a sustained reduction in blood pressure. The pharmacological action is documented to maintain a consistent antihypertensive effect for 24 hours, which is the basis for its once-daily administration schedule.

Q: What happens if I miss a dose of Noliterax?

If a dose of Noliterax is missed, official instructions advise that you do not take a double dose to compensate. Instead, official instructions advise that the next scheduled dose be taken at the usual time on the following day.

Q: Can Noliterax cause weight gain?

Official safety profiles do not typically list weight gain as a common or frequent adverse reaction. However, regulatory information for the diuretic component warns that sudden, unexplained weight change may be a sign of a serious complication related to fluid balance that is documented as requiring medical review.

Q: Will Noliterax make me feel tired or fatigued?

Yes, regulatory safety documents list tiredness and fatigue as possible common adverse effects associated with the use of the medicine. These effects may be linked to the reduction in blood pressure, and their occurrence is noted in official safety information.

Q: Can women who are planning pregnancy take Noliterax?

Official prescribing information advises that the medicine should not be initiated during pregnancy. Because use is strictly contraindicated (must not be used) in the later stages of pregnancy, patients who are planning to become pregnant are advised to consult with their prescriber to switch to an alternative treatment.

Q: Do studies show Noliterax helps reduce the risk of [outcome]? (e.g., stroke)

Regulatory documents confirm that large-scale research programs have examined the combination's effect on cardiovascular risk reduction. Evidence specifically notes that the treatment was studied for its effect on reducing the risk of major cardiovascular events, including non-fatal stroke and heart attack, in specific high-risk adult patient populations.

Q: What is the typical timeframe for seeing the full effect of Noliterax?

The full antihypertensive effect of any specific dose is generally assessed after approximately four weeks of continuous treatment. If the desired blood pressure control is not achieved after this period, a dosage adjustment (or titration) is typically assessed by the prescriber.

Q: Can Noliterax affect my cholesterol levels?

Official safety profiles indicate that the diuretic component (Indapamide) may cause changes in serum lipids, which are the fats in the blood. This can include temporary elevated triglycerides and cholesterol levels, which is a metabolic change that may require monitoring.

Q: Does Noliterax affect sleep or cause insomnia?

The official safety information lists trouble sleeping or insomnia as a less common adverse reaction associated with the medication. Persistent sleep disturbances are symptoms noted in official documentation to discuss with a healthcare professional.

Q: Are there any long-term side effects of Noliterax I should know about?

Regulatory documentation indicates that long-term data on the combination is primarily limited to the four-to-five-year follow-up period of the original clinical studies. Therefore, continued, periodic monitoring of renal function (kidney health) and blood electrolytes is documented as necessary for individuals continuing long-term therapy.

Q: Are there any foods or drinks I should avoid while taking Noliterax?

Official warnings advise that alcohol (ethanol) should be avoided or used with caution, as it can potentiate (increase) the medicine's blood pressure-lowering effect. No other specific food items are listed as being strictly prohibited in the primary regulatory documentation.

Q: Does Noliterax interact with herbal supplements?

The official prescribing information warns against the co-administration of Potassium Salts/Substitutes, which can be present in some supplements, due to the documented risk of developing dangerously high potassium levels (hyperkalaemia). Official safety documentation advises that patients inform their prescriber about all supplements they are using.

Q: What happens if I stop taking Noliterax suddenly?

The medicine is prescribed for the sustained, long-term management of a chronic condition, essential hypertension. Abruptly stopping any blood pressure medication is generally not advised by regulatory bodies, as this may lead to an uncontrolled and potentially harmful increase in blood pressure.

Q: Can Noliterax cause problems with blood sugar?

Official safety profiles for the diuretic component (Indapamide) indicate a potential for changes in blood glucose levels, including an increase in blood sugar. For this reason, regular monitoring may be assessed, particularly in patients with diabetes.

Q: Does Noliterax affect how my kidneys work?

Yes, both active ingredients influence kidney function. The diuretic component works by increasing the kidney's excretion of salt and water, while the ACE inhibitor component also modulates processes within the renal system. Due to these mechanisms, periodic monitoring of renal function is required.

Q: What if I have diabetes, can I still take Noliterax?

Regulatory documents do not list diabetes as a general contraindication (a reason it must not be used) for the medicine. However, the medicine is strictly prohibited if a patient has diabetes and is also taking a specific type of blood pressure medication called Aliskiren.

Q: Is Noliterax considered a 'first-line' treatment?

The medicine is approved by regulatory bodies for the management of essential hypertension. The decision regarding its specific role in a patient's overall treatment plan is an individualized clinical judgment that is based on established national and international treatment guidelines.

Q: Is Noliterax a diuretic?

Noliterax is a fixed-dose combination (FDC) medicine. It is not classified as a diuretic alone, but it contains one as an active ingredient: Indapamide, which is a thiazide-like diuretic. The second ingredient is the ACE inhibitor Perindopril.

Q: Can Noliterax affect my ability to drive?

Official prescribing information advises that the medicine can cause certain side effects like dizziness, tiredness, or low blood pressure (hypotension). These effects may be more pronounced at the start of treatment or following a dose increase and can affect the ability to drive or use heavy machinery.

Q: Can Noliterax cause joint pain?

Official safety documents list joint pain as a less common adverse reaction associated with the use of the medicine. This is a symptom noted in official documentation that is appropriate to discuss with a healthcare professional.

Q: Is there a risk of developing a rash while on Noliterax?

Official safety documents list a common type of skin rash as a less common adverse reaction associated with the use of the medicine. This is considered distinct from the rare but serious severe skin reactions that are also documented.

How should Noliterax be stored and disposed of?

How to Store and Dispose of Noliterax

The storage and disposal requirements for Noliterax (perindopril arginine and indapamide) are strictly defined by regulatory labeling to ensure product stability and environmental safety.

Official Storage Conditions

Requirement Description
Temperature Store below 30 C (86 F).
Protection Must be protected from moisture.
Container Rule Keep in the original container with the cap tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal Protocol

Any unused medicine or waste material must be disposed of according to local requirements. The product should not be thrown into wastewater or household waste, as proper disposal methods help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noliterax found in:

A-Z Index: